Neurophet announced on Tuesday that it has entered into a memorandum of understanding (MOU) with Eisai Korea for the supply and operation of a dementia screening and diagnostic service based on their brain neurodegeneration imaging analysis software, Neurophet AQUA.
The MOU aims to implement the Neurophet AQUA-based dementia screening and diagnostic service in medical institutions and screening centers across the country.
Under this agreement, Neurophet and Eisai Korea will collaborate to establish quality control measures and standardized procedures for dementia testing services using Neurophet AQUA. They will also work on enhancing the service based on the collection and analysis of relevant academic and clinical data.
As part of the agreement, Neurophet will be responsible for supplying and ensuring the quality of Neurophet AQUA, providing operational manuals and technical support for dementia testing, and maintaining and improving the analysis system for dementia test results.
Eisai Korea’s role will include facilitating service implementation through its network of hospitals and screening centers, conducting sales and marketing activities targeting medical institutions, and developing market analysis and strategies to expand service utilization.
Eisai Korea, the Korean subsidiary of Japanese pharmaceutical giant Eisai, is a research and development (R&D) focused company specializing in neurology and oncology. In late November 2024, it introduced Leqembi (generic name: lecanemab), an Alzheimer’s treatment drug, to the Korean market. The drug is intended for adult patients with mild cognitive impairment or mild Alzheimer’s disease.
Ko Hong-byeong, Chief Executive Officer (CEO) of Eisai Korea, expressed enthusiasm about the partnership, stating that this collaboration with Neurophet will enable them to establish quality control and standardized procedures for Neurophet AQUA-based dementia testing services in hospitals and screening centers. It is thrilled to work with Neurophet, a company that has demonstrated global competitiveness in imaging analysis for Alzheimer’s treatment prescriptions.
Bin Jun-gil, co-CEO of Neurophet, emphasized the significance of the MOU, saying that this agreement will improve access to dementia testing services that utilize artificial intelligence (AI) based brain imaging analysis solutions. It is are committed to providing technical support and delivering dementia testing services that offer tangible benefits to patients suffering from this condition.